| Overview |
| bsm-54064r |
| CXCR3 Recombinant Antibody |
| WB, IHC-P, IF(ICC) |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| Human CXCR3 aa 250-350 |
| Monoclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 2833 |
| P49682 |
| C-X-C chemokine receptor type 3, CKR-L2, G protein-coupled receptor 9, Interferon-inducible protein 10 receptor, CXC-R3, CXCR-3, IP-10 receptor, IP-10 receptor, CD183, CXCR3, GPR9 |
| Isoform 1: Receptor for the C-X-C chemokine CXCL9, CXCL10 and CXCL11 and mediates the proliferation, survival and angiogenic activity of human mesangial cells (HMC) through a heterotrimeric G-protein signaling pathway. Binds to CCL21. Probably promotes cell chemotaxis response. Isoform 2: Receptor for the C-X-C chemokine CXCL4 and also mediates the inhibitory activities of CXCL9, CXCL10 and CXCL11 on the proliferation, survival and angiogenic activity of human microvascular endothelial cells (HMVEC) through a cAMP-mediated signaling pathway. Does not promote cell chemotaxis response. Interaction with CXCL4 or CXCL10 leads to activation of the p38MAPK pathway and contributes to inhibition of angiogenesis. Overexpression in renal cancer cells down-regulates expression of the anti-apoptotic protein HMOX1 and promotes apoptosis. Isoform 3: Mediates the activity of CXCL11. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(ICC) |
1:50-200 |
Powered by Bioz